HELP

Company Overview — What Does CYBIN INC. Do?

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada. CYBIN INC. (HELP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Douglas L. Drysdale and employs approximately 50 people. With a market capitalization of $249M, HELP is one of the notable companies in the Healthcare sector.

CYBIN INC. (HELP) Stock Rating — Avoid (April 2026)

As of April 2026, CYBIN INC. receives a Avoid rating with a composite score of 25.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.HELP ranks #4,341 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CYBIN INC. ranks #795 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HELP Stock Price and 52-Week Range

CYBIN INC. (HELP) currently trades at $5.18. The stock lost $0.06 (1.1%) in the most recent trading session. The 52-week high for HELP is $8.97, which means the stock is currently trading -42.3% from its annual peak. The 52-week low is $4.52, putting the stock 14.6% above its annual trough. Recent trading volume was 210K shares, suggesting relatively thin trading activity.

Is HELP Overvalued or Undervalued? — Valuation Analysis

CYBIN INC. (HELP) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.59x, versus the sector average of 2.75x.

At current multiples, CYBIN INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CYBIN INC. Profitability — ROE, Margins, and Quality Score

CYBIN INC. (HELP) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -190.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -175.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HELP Debt, Balance Sheet, and Financial Health

CYBIN INC. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $94M.

HELP has a beta of 2.45, meaning it is more volatile than the broader market — a $10,000 investment in HELP would be expected to move 145.0% more than the S&P 500 on any given day. The stability factor score for CYBIN INC. is 24/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CYBIN INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CYBIN INC. reported revenue of $0 and earnings per share (EPS) of $-3.89. Net income for the quarter was $-79M. Operating income came in at $-100M.

In FY 2025, CYBIN INC. reported revenue of $0 and earnings per share (EPS) of $-3.89. Net income for the quarter was $-79M. Operating income came in at $-100M.

In FY 2024, CYBIN INC. reported revenue of $0 and earnings per share (EPS) of $-6.95. Net income for the quarter was $-58M. Operating income came in at $-58M.

In FY 2023, CYBIN INC. reported revenue of $0 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-35M. Operating income came in at $-38M.

Over the past 5 quarters, CYBIN INC. has experienced revenue contraction from $0 to $0. Investors analyzing HELP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HELP Dividend Yield and Income Analysis

CYBIN INC. (HELP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HELP Momentum and Technical Analysis Profile

CYBIN INC. (HELP) has a momentum factor score of 24/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 56/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 25/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

HELP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CYBIN INC. (HELP) ranks #795 out of 838 stocks based on the Blank Capital composite score. This places HELP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HELP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HELP vs S&P 500 (SPY) comparison to assess how CYBIN INC. stacks up against the broader market across all factor dimensions.

HELP Next Earnings Date

No upcoming earnings date has been announced for CYBIN INC. (HELP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HELP? — Investment Thesis Summary

The quantitative profile for CYBIN INC. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 24/100, a headwind for near-term performance. High volatility (stability score 24/100) increases portfolio risk.

In summary, CYBIN INC. (HELP) earns a Avoid rating with a composite score of 25.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HELP stock.

Related Resources for HELP Investors

Explore more research and tools: HELP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HELP head-to-head with peers: HELP vs AZN, HELP vs SLGL, HELP vs VMD.